Expression Pathology Signs Biomarker Discovery Deal with Digene
News Dec 21, 2005
Expression Pathology Inc. has announced that it has entered into research collaboration with Digene Corporation to identify cancer protein biomarkers in archived tissue using Expression Pathology’s proprietary Microproteomics Biomarker Discovery platform.
Under the terms of the agreement, Expression Pathology will employ its Liquid Tissue™ MS Protein Prep reagents with LC MS/MS mass spectrometry to identify proteins in microdissected formalin-fixed tissue of known pathology and clinical history.
Getting to Know the Microbes that Drive Climate ChangeNews
A new understanding of the microbes and viruses in the thawing permafrost in Sweden may help scientists better predict the pace of climate change.READ MORE
Hidden Signals in RNAs Regulate Protein SynthesisNews
Scientists have long known that RNA encodes instructions to make proteins. In a new study published in Nature, scientists describe how the protein-making machinery identifies alternative initiation sites from which to start protein synthesis.READ MORE